Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study
Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study
The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of tiotropium. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.
Main Inclusion Criteria:
Main Exclusion Criteria:
Landsberg/Lech, 86899, Germany
Hódmezovásárhely, 6800, Hungary
Nyiregyháza, 4412, Hungary
Cisanello (PI), 56100, Italy
Escaldes-Engordany, AD700, Spain
Mostoles Madrid, 28935, Spain
Atherstone, Warwick, CV9 1EU, United Kingdom
Bolton Lancs, BL3 6TL, United Kingdom
Chesterfield Derbyshire, S40 4TF, United Kingdom
Co. Antrim, BT38 8TP, United Kingdom
East Sussex, TN39 5HE, United Kingdom